[HTML][HTML] Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
K Nosaki, M Satouchi, T Kurata, T Yoshida, I Okamoto… - Lung cancer, 2016 - Elsevier
Objective Disease progression because of acquired resistance is common in advanced or
metastatic epidermal growth factor receptor (EGFR)-mutation positive non-small cell lung …
metastatic epidermal growth factor receptor (EGFR)-mutation positive non-small cell lung …
Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
T Kawamura, H Kenmotsu, T Taira, S Omori… - Cancer …, 2016 - Wiley Online Library
Although third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitors
(EGFR‐TKI) can overcome T790M‐mediated resistance in non‐small‐cell lung cancer …
(EGFR‐TKI) can overcome T790M‐mediated resistance in non‐small‐cell lung cancer …
Feasibility of rebiopsy in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors
T Hasegawa, T Sawa, Y Futamura, A Horiba… - Internal …, 2015 - jstage.jst.go.jp
Objective Analyses of tumor biopsy samples from non-small cell lung cancer patients with
acquired epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance …
acquired epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance …
[PDF][PDF] Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
Purpose Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting
acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) …
acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) …
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR …
R Ko, H Kenmotsu, M Serizawa, Y Koh, K Wakuda… - BMC cancer, 2016 - Springer
Background The majority of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutation eventually develop resistance to EGFR tyrosine …
growth factor receptor (EGFR) mutation eventually develop resistance to EGFR tyrosine …
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
JL Kuiper, DAM Heideman, E Thunnissen, MA Paul… - Lung cancer, 2014 - Elsevier
Aim Non-small cell lung cancer (NSCLC)-patients with an epidermal growth factor receptor
(EGFR)-mutation have median progression-free survival (PFS) of 12 months on tyrosine …
(EGFR)-mutation have median progression-free survival (PFS) of 12 months on tyrosine …
Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non–small-cell lung cancer
T Kawamura, H Kenmotsu, S Omori, K Nakashima… - Clinical lung cancer, 2018 - Elsevier
Background T790M, a secondary epidermal growth factor receptor (EGFR) mutation,
accounts for approximately 50% of acquired resistance to EGFR-tyrosine kinase inhibitors …
accounts for approximately 50% of acquired resistance to EGFR-tyrosine kinase inhibitors …
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has …
R Minari, G Mazzaschi, P Bordi, L Gnetti, G Alberti… - Clinical Lung Cancer, 2020 - Elsevier
Background In advanced epidermal growth factor receptor (EGFR)-mutated non–small-cell
lung cancer (NSCLC) patients whose disease has progressed during treatment with first-and …
lung cancer (NSCLC) patients whose disease has progressed during treatment with first-and …
Role of rebiopsy in relapsed non‐small cell lung cancer for directing oncology treatments
AP Jekunen - Journal of oncology, 2015 - Wiley Online Library
Background. Currently, few rebiopsies are performed in relapses of advanced non‐small
cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not …
cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not …
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Cancer, 2013 - Wiley Online Library
BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
相关搜索
- small cell lung cancer
- t790m mutation lung cancer
- growth factor lung cancer
- receptor tyrosine lung cancer
- clinical factors lung cancer
- acquired resistance kinase inhibitor
- acquired resistance rebiopsy samples
- feasibility of rebiopsy kinase inhibitors
- acquired resistance japanese patients
- japanese patients rebiopsy samples
- growth factor receptor tyrosine
- t790m mutation nsclc patients
- receptor tyrosine kinase inhibitor
- growth factor acquired resistance
- growth factor kinase inhibitor
- receptor tyrosine acquired resistance